Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding...

Lonza has entered into a collaboration with Touchlight, a biotechnology company with patented technology for producing enzymatic DNA. The enzymatic manufacturing process...

Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical...

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...

Lonza and Israel Biotech Fund (IBF) have signed a framework agreement, under which the Swiss CDMO will provide advice and support for Israeli biotech companies. IBF is...

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.

Germany’s Merck has acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed sum. The Darmstadt-based chemicals, pharmaceuticals and life...

Swiss CDMO Lonza has signed an agreement for the large-scale manufacture of the main drug intermediate for Swedish specialty pharma Oasmia’s investigational cancer drug...